Clinical Trial

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Study acronym: MorningLyte
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.
Trial Details
NCT Number NCT06284122
Lead Sponsor The Lymphoma Academic Research Organisation
Collaborators: Lymphoma Study Association, Swiss Cancer Institute, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Conditions Follicular Lymphoma
Enrollment 790 participants
Start Date 2024-06-07
Primary Completion 2028-11 (estimated)
Study Completion 2034-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-05